EnricaMarchiMD
Oncology • Charlottesville, VAHematologic Oncology
Assistant Professor of Medicine, Microbiology, Immunology and Cancer Biology; Co-Director Program for T-Cell Lymphoma Research; Division of Hematology Oncology; Department of Medicine; University of Virginia
Dr. Marchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1240 Lee St
Charlottesville, VA 22908Phone+1 434-924-9333Fax+1 434-244-7526
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2015 - 2018
Lincoln Medical and Mental Health CenterResidency, Internal Medicine, 2012 - 2015
New York University School of MedicinePost-Doctoral Fellowship, 2009 - 2011
Columbia University Vagelos College of Physicians and SurgeonsPost-Doctoral Fellowship, 2007 - 2009
University of BolognaClass of 2002
Certifications & Licensure
VA State Medical License 2020 - 2026
NY State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Start of enrollment: 2021 Feb 19
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium.Jessy Xinyi Han, Min Jung Koh, Leora Boussi, Mark Sorial, Sean M McCabe
Blood Advances. 2025-02-11 - 1 citationsCurrent and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL).Enrica Marchi, Jeffrey W Craig, Matko Kalac
Blood. 2024-10-31 - Tumor flare reaction in a patient with mycosis fungoides treated with a novel immune-epigenetic doublet.Nakul Dar, Nathan Roberts, Alejandro Gru, Ifeyinwa Obiorah, Jiefu Zheng
JAAD Case Reports. 2024-06-01
Press Mentions
UVA Cancer Center Receives $5.75 Million to Battle Rare Blood CancersAugust 4th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
